首页> 外文期刊>Life sciences >A synthetic analog of prostaglandin E(1) prevents the production of reactive oxygen species in the intestinal mucosa of methotrexate-treated rats.
【24h】

A synthetic analog of prostaglandin E(1) prevents the production of reactive oxygen species in the intestinal mucosa of methotrexate-treated rats.

机译:前列腺素E(1)的合成类似物可防止甲氨蝶呤治疗的大鼠肠粘膜中产生活性氧。

获取原文
获取原文并翻译 | 示例
           

摘要

Administration of methotrexate to rats results in severe enterocolitis and death. Previous our studies showed that a synthetic analog of prostaglandin E(1), OP-1206 [17S, 20-dimethyl-trans-Delta(2)-prostaglandin E(1)] ameliorated the anticancer agent-induced enterocolitis of rats. In the current study, we have focused on the biochemical effect of OP-1206 on the methotrexate-induced intestinal inflammation implicating reactive oxygen species (ROS). Methotrexate (15 mg/kg body weight) was orally administered to rats once daily for 5 days. OP-1206 (0.5 microg/kg body weight) was orally administered to rats twice a day for 5 days. On the 6th day, the chemiluminescence from the jejunum was measured to evaluate the generation of ROS. Spontaneous chemiluminescence from the jejunum of the methotrexate-treated rats increased significantly, compared with the control. Luminol-enhanced chemiluminescence from inflamed mucosal scrapings from the jejunum of the methotrexate-treated rats indicated more remarkable enhancement than the control rats. The treatment of OP-1206 with methotrexate showed significantly lower chemiluminescence of both the jejunum and mucosal scrapings than those of the methotrexate-treated rats. The alkaline phosphatase (ALP) activity, as a marker of small intestinal differentiation, in the intestinal mucosa of the methotrexate-treated rats decreased remarkably, but that of the methotrexate and OP-1206-treated rats was significantly higher than that of the methotrexate-treated rats. Thus, OP-1206 may possibly help the anticancer chemotherapy by protecting the small intestine from the methotrexate-induced damage.
机译:给大鼠服用甲氨蝶呤会导致严重的小肠结肠炎和死亡。先前的研究表明,前列腺素E(1),OP-1206 [17S,20-二甲基-反式-Delta(2)-前列腺素E(1)]的合成类似物改善了抗癌剂诱导的大鼠小肠结肠炎。在当前的研究中,我们集中于OP-1206对甲氨蝶呤诱导的肠道炎症涉及活性氧(ROS)的生化作用。每天一次对大鼠口服甲氨蝶呤(15 mg / kg体重),持续5天。每天两次向大鼠口服OP-1206(0.5微克/千克体重),持续5天。在第6天,测量来自空肠的化学发光以评估ROS的产生。与对照相比,甲氨蝶呤治疗的大鼠空肠的自发化学发光显着增加。甲氨蝶呤治疗的大鼠空肠发炎的粘膜刮擦产生的鲁米诺增强化学发光,显示出比对照组更显着的增强。与甲氨蝶呤治疗的大鼠相比,用甲氨蝶呤治疗OP-1206的空肠和粘膜刮擦的化学发光显着降低。甲氨蝶呤治疗组大鼠肠粘膜中碱性磷酸酶(ALP)活性作为小肠分化的标志物显着降低,但甲氨蝶呤和OP-1206治疗组大鼠的肠粘膜中碱性磷酸酶活性显着高于甲氨蝶呤治疗组治疗的大鼠。因此,OP-1206可能通过保护小肠免受甲氨蝶呤引起的损害而帮助抗癌化学疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号